Cotsiranib

科特拉尼

Report date: 2022/09/09 14:31:15
NME

Base Information

Drug NameCotsiranib
Drug Alias NameAnti-fibrosis RNA interference therapeutic - SirnaomicCutasilSTP-705LSTP-705LUSTP-705LV +[6] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionTransforming growth factor beta 1 inhibitorsCyclooxygenase-2 inhibitorsRNA interference
TargetsCyclooxygenase-2Transforming growth factor beta 1
Therapy Area/IndicationsCicatrix, HypertrophicObesity, AbdominalKeloid +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTaiwanMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaClinical
Originator CompaniesSirnaomicsSirnaomics Biopharmaceuticals (Suzhou) Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesSirnaomicsSirnaomics LtdGuangzhou Xiangxue Pharmaceutical Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsCicatrix, HypertrophicObesity, AbdominalKeloid +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A